Bart Neyns

Researcher Next ID · RN-007861

Researcher · Medicine

Brussels, Belgium

Not currently recruitingFunding unknown

Research interests

Medicine

Immunology and Microbiology

Biochemistry, Genetics and Molecular Biology

Cancer Immunotherapy and Biomarkers

Glioma Diagnosis and Treatment

Immunotherapy and Immune Responses

CAR-T cell therapy research

Melanoma and MAPK Pathways

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
Journal of Clinical Oncology · 2018 · https://doi.org/10.1200/jco.2017.76.9901
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
The Lancet · 2017 · https://doi.org/10.1016/s0140-6736(17)31601-x
Pembrolizumab versus Ipilimumab in Advanced Melanoma
New England Journal of Medicine · 2015 · https://doi.org/10.1056/nejmoa1503093
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
The Lancet Oncology · 2015 · https://doi.org/10.1016/s1470-2045(15)70076-8
Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer
Journal of Clinical Oncology · 2007 · https://doi.org/10.1200/jco.2006.08.1620

No projects listed.